Skip to main content
OpenTrials
Completed

NCT Number: NCT00983658

A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of allergen-induced asthma.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Weight between 50 and 125 kg
  • Mild, stable allergic asthma
  • History of episodic wheeze and shortness of breath
  • FEV1 at baseline ≥ 70% of the predicted value
  • For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the study
  • For men with partners of childbearing potential, willingness to use condoms with spermicide during treatment
  • Ability to comprehend and follow all required study procedures
  • Positive skin prick test to common aeroallergens (e.g., cat, dust, mite, grass, and pollen)
  • Positive allergen-induced early and late airway bronchoconstriction

Exclusion criteria

  • A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry
  • Acute infection (including viral infection) within the 6 weeks preceding dosing (8 weeks for respiratory infections) or any ongoing chronic infection
  • History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition, including (but not limited to), tuberculosis, parasitic infection, etc.
  • Lung disease other than mild allergic asthma
  • History of heart, lung, kidney, liver, neurologic or chronic infectious disease
  • Concomitant disease or condition, which could interfere with the conduct of the study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease
  • History of serious adverse reaction or hypersensitivity to any drug
  • Pregnancy or lactation or positive serum pregnancy test at screening
  • Chronic use of any other medication for treatment of allergic lung disease other than short-acting β2-agonists or ipratropium bromide
  • Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule within the past 5 months (5 half-lives of the drug), including omalizumab
  • Regular use of tobacco products of any kind or within the previous 6 months, or smoking history > 10 pack-years

Treatment and study plan

huMAb OX40L

Drug

Intravenous repeating dose

Placebo

Drug

Intravenous repeating dose

Primary outcomes

  1. The primary outcome measure is the late asthmatic response (LAR) in patients treated with huMAb OX40L versus placebo

    Time frame: 16 weeks after the first dose

Secondary outcomes

  1. LAR after the allergen challenge in patients treated with huMAb OX40L versus placebo

    Time frame: Approximately Day 56 prior to third dose

  2. Change in methacholine challenge response relative to the pre-allergen challenge PC20

    Time frame: 24 hours after each allergen challenge

  3. Early asthmatic response (EAR) in patients treated with huMAb OX40L versus placebo

    Time frame: Between 0 and 2 hours after each allergen challenge

  4. Incidence and nature of treatment-emergent adverse events

    Time frame: Through study completion or early study discontinuation

  5. Incidence and nature of infusion reactions

    Time frame: Through study completion or early study discontinuation

  6. Incidence of infectious complications

    Time frame: Through study completion or early study discontinuation

  7. Incidence, nature, relatedness, and severity of adverse events

    Time frame: Through study completion or early study discontinuation

  8. Clinically significant changes in vital signs, electrocardiograms, FEV1, and safety laboratory measures

    Time frame: Through study completion or early study discontinuation

  9. Incidence of anti-therapeutic antibodies

    Time frame: Through study completion or early study discontinuation

Sponsors and collaborators

Lead sponsor

Genentech, Inc.

Industry

Registry information

Official study title

A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

Important dates

Study start
2009
Primary completion
2010
Study completion
2011
First posted
Sep 24, 2009
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.